New Oasis album is almost complete & other: 2008

Tuesday 2 September 2008

Pick of the week: Classical and opera

Beaux Arts Trio
Queen's Hall, Edinburgh
Saturday 30
The utmost ever British concert from the illustrious chamber group.

A Child Of Our Time
Usher Hall, Edinburgh
Saturday 30
Tippett's anti-fascist cantata ends the international festival.

Scottish Chamber Orchestra
Concert Hall, Motherwell, Wednesday 3 Sept;
Town Hall, Falkirk, Thursday 4 Sept;
Town Hall, Paisley, Friday 5 Sept
Aleksander Markovic conducts.

More info

Saturday 23 August 2008

Coldplay make plans for next album release

The follow-up to Coldplay's Viva La Vida album could hit shelves as early as next year, according to a report.

Chris Martin and his bandmates already have a routine of tracks lined up for the record following successful studio sessions with Brian Eno.

A source told The Sun: "The Viva La Vida sessions were incredibly fruitful. They gelled brilliantly with Brian and recorded much more music than they could fit on one album.

"The majority of the follow-up is already in the crapper, though they will stimulate to go back into the studio at some point to add a few more songs."

The newspaper also claimed that releasing the album would take Coldplay a step closer to going the EMI label, which has already been strike hard by the departures of Paul McCartney and Radiohead.

However, an EMI interpreter told DS: "Contrary to inaccurate reports in The Sun, Coldplay are sign-language to a long terminal figure record dole out with EMI and ar committed to produce a number of albums. The band's relationship with EMI is both long-term and positive."

More information

Wednesday 13 August 2008

New Data Shows HIV Therapy Tipranavir (Aptivus�) Is Effective And Well Tolerated In Children

�Boehringer Ingelheim presented new 100 week data at the International AIDS Conference demonstrating Aptivus� (tipranavir) long-term efficacy and safety in treatment-experienced children. Results from this two-year study show that Aptivus� enabled the children to achieve free burning virologic and immunologic responses and was a well-tolerated antiretroviral therapy.

These results build on the positive 48 week information presented in 2006 at the International AIDS Conference in Toronto and submitted to the FDA for the recent approval of the Aptivus� paediatric oral solution and paediatric reading in the United States: Data which is also currently organism reviewed by the EMEA for a paediatric and oral solution licences in Europe.

This biennial follow-up data evaluated tipranavir co-administered with low dosage ritonavir (Aptivus/r) in 78 treatment-experienced children. Those complementary the original 48 week trial were given the choice of continuing their therapy with Aptivus� for an propagation of the trial. The continuing analysis confirms the results of the 48 week information and demonstrates the lastingness of Aptivus�. Over half of jr. children in the trial achieved free burning virologic reply and the oral solution continued to be well tolerated over the 100 weeks.

Dr. Manfred Haehl, Corporate Senior Vice President Medicine at Boehringer Ingelheim said, "We ar pleased that tipranavir showed such a positive efficaciousness and base hit profile in treatment-experienced children who hold fewer treatment options than adults and need more than therapy choices, including therapies that cause been especially formulated to meet their needs."

The number of children diagnosed with HIV/AIDS is growing. There are just about 2.1 million children living with HIV worldwide and recent statistics bear witness that some other 29,000 will be infected with the disease this year alone.1 Once a child is infected with HIV, they face a higher chance of development AIDS unless they crapper successfully be treated with antiretroviral therapy. Just as with adults, children canful become resistant to certain therapies which underscores the need for an addition in intervention options active against drug-resistant HIV.

The data, collected in over 26 sites in Europe, the United States and Latin America, shows that HIV-1 positive children and adolescents receiving tipranavir boosted by ritonavir as part of their combination antiretroviral therapy can reach sustained virologic and immunological responses at 100 weeks of therapy: after C weeks of treatment, 56% of children between 2 and 6 years achieved a viral load of less than 400 copies per ml, and 48% of this age chemical group saw their viral rafts drop to undetectable levels (less than 50 copies per ml).

For the 6 to 12 years old group, 30% achieved an undetectable viral load (less than 50 copies per ml), and for the 12 to 18 eld old grouping, still over 20% achieved an undetectable viral load. The lower rate of undetectable viral loads in older children is due to them being more treatment-experienced and harbouring HIV which has become more drug-resistant than in younger children.

"There are many children and adolescents with HIV who run out to maintain viral inhibition of the disease, which speaks to the pressing need for a new generation of therapies intentional specifically for this group," noted lead author of the analysis and Associate Professor of Paediatrics, Dr. Juan Salazar, MD, MPH, Connecticut Children's Medical Centre, Hartford, CT, USA. "For these treatment-experienced children world Health Organization have had limited options for maintaining an active and long-wearing treatment regimen, we now have evidence that tipranavir is effective and tolerable."

Up to 50% of HIV-infected children and adolescents flush it to maintain suppression of HIV echo beyond two years of initial discussion, according to some studies,2,3 and up to 90% of children who fail antiviral therapy carry drug-resistant strains of HIV. These statistics make it critical that new options ar made available which are able to suppress HIV in the treatment-experienced pediatric group.

The to the highest degree common incline effect was gastrointestinal effects such as vomiting and diarrhoea, piece over 6% of patients experienced Grade 3 liver enzyme rises (ALT). None of the patients experient Grade 4 ALT elevations, indicating an acceptable hepatoxicity profile.

About Aptivus�

Aptivus� is a non-peptidic protease inhibitor which workings by inhibiting the viral protease, an enzyme required to complete the HIV replication treat. Based on available clinical and in vitro data, Aptivus� is active against to the highest degree strains of HIV-1 that are immune to commercially available proteolytic enzyme inhibitors. It is approved for combination antiretroviral intervention of HIV-1 infected adults that are highly pre-treated with virus resistant to multiple peptidase inhibitors.

RESIST I and II two large-scale clinical studies on Aptivus� involving more than 1,400 patients formed the foundation for granting traditional approval by the FDA and replete marketing sanction by the EMEA. The RESIST clinical trial program is one of the largest study programs undertaken with an investigational antiretroviral agent in patients previously treated with multiple combinations of antiretroviral drug regimens.

Aptivus� can be combined with new agents with novel mechanisms of action (e.g. integrase inhibitors and CCR-5 antagonists) without dose adjustment to build efficacious and perdurable treatment regimens. Such a benefit has been clearly demonstrated by favourable results with the concomitant use of APTIVUS in combination with modern drug classes.4,5

The most normally reported side effects of at least moderate intensiveness in patients enrolled in the RESIST studies pickings Aptivus� are gastrointestinal, including diarrhoea, sickness, vomiting and abdominal painfulness. Fever, weariness, headache, bronchitis, depression and rash besides occurred. Elevated transaminase, cholesterol and triglycerides were more frequent in the Aptivus�/r arm than in the ritonavir boosted comparator radical but only in a minority of cases treatment discontinuation was necessary.

Aptivus� boosted with low-dose ritonavir has been associated with reports of hepatic adverse events, which experience included some fatalities. These have broadly occurred in patients with advanced HIV disease pickings multiple co-occurrence medications. Extra vigilance is warranted in patients with chronic hepatitis B or hepatitis C co-infection, as these patients have an increased peril of liver toxicity. The most common moderate to severe testing ground abnormalities were elevated liver enzymes and elevated lipide levels. Most laboratory abnormalities were symptomless and to the highest degree patients were successfully treated without discontinuation.

Aptivus�-containing HAART regimens have been associated with reports of both black and nonfatal intracranial haemorrhage (ICH) in some highly treatment-experienced patients. Caution should be used when prescribing Aptivus�/r in patients world Health Organization may be at risk of exposure of increased bleeding or who ar receiving medications known to increase the risk of bleeding.

Aptivus� does not cure HIV infection/AIDS or forestall the transmittal of HIV to others. Patients crataegus oxycantha continue to develop timeserving infections and other complications associated with HIV disease.

Aptivus� received U.S. marketing sanction by the U.S. Food and Drug Administration (FDA) and was launched in the Unites States in June 2005. On October 4th, 2007, the FDA granted traditional approval for Aptivus�, and in April 2008 the EMEA granted full marketing authorisation for Aptivus� in Europe. Additional marketing authorizations from different countries give been standard or ar expected.

Aptivus� OS (oral solution) received U.S. marketing say-so for use in treatment experienced children and adolescents by the U.S. Food Drug Administration (FDA) on 24 June 2008.

About Boehringer Ingelheim HIV Clinical Trials

Boehringer Ingelheim is actively conducting clinical trial programs to further evaluate Aptivus� and the non-nucleoside-reverse transcriptase inhibitor (NNRTI) Viramune� for the discourse of HIV-1 infection.

The Viramune� clinical test program includes the ArTEN trial, which aims to compare the efficacy and safety of Viramune dosed once or twice day-after-day versus atazanavir boosted with ritonavir in HIV-positive antiretroviral-na�ve patients. The ArTEN trial will enrol 561 HIV-positive patients wHO have yet to be treated with antiretrovirals.

About Boehringer Ingelheim

Boehringer Ingelheim is committed to the research and development of novel antiretroviral agents. Apart from Aptivus� (tipranavir), Viramune� (viramune) is a product of original research done at Boehringer Ingelheim. Viramune� was the first member of the non-nucleoside reverse rNA polymerase inhibitor (NNRTI) class of anti-HIV drugs on the market. The company is involved in basic research in that area and is committed to up HIV therapy by providing physicians and patients with innovative antiretroviral treatment options.

This release is from Boehringer Ingelheim Corporate Headquarters in Germany. Please be mindful that in that respect may be national differences between countries regarding specific medical info, including licensed uses. Please take accounting of this when referring to the information provided in this document. This press release is non intended for distribution inside the U.S.A.

References:

1) AIDS Epidemic Update, December 2007, UNAIDS/WHO.

2) van Rossum AM, Geelen SP, Hartwig NG, Wolfs TF, Weemaes CM, Scherpbier HJ, et al. Results of 2 years of treatment with

Wednesday 6 August 2008

Innovative Diabetes Program In Bloomington-Normal, Ill., A Success

�
Diabetes Checks and Balances, a unparalleled program launched locally to help

Thursday 26 June 2008

Robin Williamson, The Celtic Bard

In the 'they don't make them like that anymore' stakes, Robin Williamson has carved a considerable–sized niche all of his own. Founder of Sixties' psych-folk pioneers The Incredible String Band and subsequently the short-lived The Merry Band, Williamson has ploughed a distinctively idiosyncratic path (and, for those with a penchant for it, a curiously attractive one to boot) since releasing his first solo album half a lifetime ago in 1971.

This compilation, on the Swedish Gason label, recycles material from earlier live, studio and compilation albums to offer a distinctive introduction to Williamson's many solo incarnations as a modern-day Celtic bard.

It starts with the nine-minute epic, Love Letter To My Wife Bina, a tale of cider-drinking, the Santa Fe freight train and falling in love, and ends with the Wagnerian expanse of the 15-minute-long Voyage Of Mael Duinn, a reading of heroic derring-do accompanied by an evocative combination of keyboards, jew's harp, sound effects and harp.

The harp is at the genetic core of Williamson's post-Incredible String Band musical identity, and it features here on all but one of the 18 tracks. This gives the proceedings a tonal unity, characterised by a delicate but dancing beauty. That's not to say that everything sounds the same - quite the contrary. The growling, heavy-hanging percussion accompaniment in Lady Macbeth throws the harp into unsettlingly dramatic relief while in the compact but meandering On The Way To The Cathedral, the simple purity of the harp provides a welcome counterpoint to the secret rapture of the lyrics.

It's the miniature pieces that capture the imagination. Where the gnomically titled Leslie's Joog manages to be simultaneously elegant and jaunty, The Lady And The Book offers up a compelling, nightmare-tinged narrative underlined by Williamson's pointed vocal delivery, and sweetly offset by his no less deliberate way with the harp.

For sheer individuality of conception and execution, Williamson's seductive psychedelia-tinged pastoralism has no equals, with one proviso: although it's not comparing like with like, one can't help thinking, and favourably so, of the lyric-centred Clifford T Ward and the lyric-free Andrew Cronshaw throughout this very agreeable album.

Those who know Robin Williamson will already have this album on their radar. For those who don’t, it offers a splendid introduction to a rare talent. Eccentric he may be, but he does so make you wish that there were more people making music as rough-hewn, richly executed and abidingly resonant as that on offer here.

Bizarre but strangely beautiful. File under: unique.

See Also

Thursday 19 June 2008

Panic At The Disco, Snoop Dogg launch MTV programme

Panic At The Disco will be joined on stage by Snoop Dogg as the first performers on a new weekly music programme hosted by Fall Out Boy's Pete Wentz.

'F'N MTV' premieres tomorrow (June 13) at 8pm PST/EST on MTV, and features a live performance from Panic At The Disco as well as video premieres from Snoop Dogg, The Ting Tings, The Pussycat Dolls and Flo-Rida, who will all be on-hand to introduce their videos.

Viewers can vote on the videos and upload their own re-imagined versions of them to the web.

"Having people interact with anything we're doing makes us feel complete as a band," Ting Tings' Jules De Martino told NME.COM. "It's very much about creating new ways people can get involved."

The Ting Tings' 'Shut Up And Let Me Go' video will premiere tomorrow. "We wanted to make a Kung Fu video because we've been watching a lot of Stephen Chow videos like 'Kung Fu Hustle'," De Martino explained. "We're also into using a lot of layers, shapes and colours."

The programme is scheduled to air on MTV every Friday night throughout the summer. Next week's show will feature Vampire Weekend and Duffy.

"We're bringing music videos back to MTV on a Friday night," Wentz said. "I was raised on music videos, they made me who I am today," he added.

The premiere programme will also feature a spoof segment in which Snoop Dogg gives Wentz and his new bride Ashlee Simpson tips on how to raise their forthcoming child, including putting the baby's crib in the garage so it doesn't wake them and nursing the baby with malt liquor.

--By our Los Angeles staff.
Find out more about NME.

Wednesday 11 June 2008

Cowell reveals suicidal teenage years

'American Idol' judge Simon Cowell has spoken about his teenage years, saying that he felt suicidal when he was younger.
The star told Parade that he hated school and feared that his life would not get better.
He said: "I was always bored. I didn't like the rules and I didn't like discipline."
"So when someone said to me, 'These are the best days of your life', I actually thought about jumping off a bridge."
"I was like, 'If it gets any worse than this I'm done', because I hated school and I hated my life."

Wednesday 4 June 2008

Spirallianz

Artist: Spirallianz

   Genre(s):
Trance: Psychedelic

Discography:

Silver Edition Part 3 Vinyl

Year: 2002
Tracks: 2

Sunday 1 June 2008

Minka Kelly - Kellys Warm Wishes For Mayer Aniston

Actress MINKA KELLY has given her ex-boyfriend JOHN MAYER her blessing to date former FRIENDS star JENNIFER ANISTON.

Kelly and Mayer enjoyed a four-month relationship after the rocker split with Jessica Simpson last year (07).

The couple broke up in January (08) and Mayer has subsequently been linked to Aniston, having spent several romantic weekends with the actress.

And although the pair have yet to confirm they are an item, Kelly insists she harbours no ill feelings towards her ex-lover and wishes him well if he is dating Aniston.

She tells Usmagazine.com, "I wish them the best."

See Also

Madonna - Madonna Upsets French Fans With Short Performance

Pop superstar MADONNA upset her fans in France on Tuesday night (06May08) after turning up to a concert more than two hours late.

And the Holiday hitmaker further disgruntled her followers by only giving a 40-minute performance in the nation's capital, Paris.

Dressed in a black T-shirt, trousers and big boots, she finally took to the stage on a big chair by sipping champagne directly from the bottle. She got up from the chair and kissed one of her female dancers - like she did with Britney Spears and Christina Aguilera at the 2003 MTV Video Music Awards - before performing Hard Candy.

One fan, Melanie Monnier, told WENN after the show, "She is great, but the wait and the shortness of the show were a bit disappointed. There was a real lack of emotion."

And fan Guy Juliean even doubted Madonna was performing live. He said, "The show was perfect - too perfect with no room for any emotion. Was she singing live? I'm not sure. It was good to see her but I'm a bit disappointed by her lack of charisma tonight on stage."

The singer announced her love of France and spoke of the honour of performing on the same stage as the iconic French chanteuse Edith Piaf, or fellow legends Juliette Greco and Marlene Dietrich.

She says, "Why do I have this relationship with France? I'm always drawn to working with French people - and frenching French people. Vive la France!"

Lenny Kravitz, John Galliano and Kelly Rowland were among the crowd to see her perform four singles from her new album Hard Candy, as well as Hung up and Music.

See Also

Ashanti - The Things They Say 8453

"I found out that I really like to play golf - I'm actually good." R+B star ASHANTI has become the latest golfing celebrity.

See Also

David Sylvian and Robert Fripp

Artist: David Sylvian and Robert Fripp

   Genre(s):
Rock
   New Age

Discography:

Damage (Reissue)

Year: 1994
Tracks: 12

The First Day

Year: 1993
Tracks: 7

Kings

Year: 1993
Tracks: 14

Darshan

Year: 1993
Tracks: 3

Radiohead to Prince: Unblock 'Creep' cover videos

WASHINGTON - After word spread that Prince covered Radiohead’s "Creep" at Coachella, the tens of thousands who couldn’t be there ran to YouTube for a peek. Everyone was quickly denied — even Radiohead.
All videos of Prince’s unique rendition of Radiohead’s early hit were quickly taken down, leaving only a message that his label, NPG Records, had removed the clips, claiming a copyright violation. But the posted videos were shot by fans and, obviously, the song isn’t Prince’s.
In a recent interview, Thom Yorke said he heard about Prince’s performance from a text message and thought it was "hilarious." Yorke laughed when his bandmate, guitarist Ed O’Brien, said the blocking had prevented him from seeing Prince’s version of their song.

"Really? He’s blocked it?" asked Yorke, who figured it was their song to block or not. "Surely we should block it. Hang on a moment."
Yorke added: "Well, tell him to unblock it. It’s our ... song."
YouTube prohibits the posting of copyrighted material. If the site receives a complaint from a copyright owner, it will in most cases remove the video(s). Whether the same could be done for a company not holding a copyright is less clear, but Yorke’s argument would seem to bear some credence according to YouTube’s policies. YouTube, which is owned by Google, declined to comment.
Prince also did not immediately respond to a request for comment Thursday.
The dispute was an interesting twist in debates over digital ownership, held between two major acts with differing views on music and the Internet. Radiohead famously released their most recent album, "In Rainbows," as a digital download with optional pricing. They also have a channel on YouTube.
When Prince performed at the Coachella Valley Music and Arts Festival in Indio, Calif., on April 26, he prohibited the standard arrangement of allowing photographers to shoot near the stage during the first three songs of his set. Instead, he had a camera crew filming his performance.
Prince, who founded NPG Records in 1993, has been innovative when it comes to music distribution, too. He released his 1997 album, "Crystal Ball," on the Internet and in 2006 was awarded a lifetime achievement award by the Webbys. In 2007, he gave away copies of his disc "Planet Earth" in a British Sunday newspaper.
But the Purple One has also shut down his official Web site and in September of last year said he would sue YouTube and eBay for not filtering unauthorized content.
Prince fans have organized to urge him to relent in his legal fights to control images and photographs of himself. As of Thursday, the most popular YouTube clip about Prince playing "Creep" is an expletive-laden rant from Sam Conti Jr., who describes himself as a "former Prince fan."

Ash aim to whip up a storm

ASH will be headlining the final day of Ben & Jerry's Sundae on the
Common.

The Irish rockers will be performing on Sunday, July 27 at Clapham Common, to
celebrate the ice cream giant's 30th birthday.

They will be supported by SLOW CLUB, CAGE THE ELEPHANT and THE
NEW YORK FUND.

The line-up for the opening day of the weekend event on Saturday, July 26 has
yet to be confirmed, but I'll let you know as soon as it's announced.

To purchase tickets, visit benjerry.co.uk

Sarah Jessica Parker Slams Paparazzi

Actress Sarah Jessica Parker has slammed the paparazzi for following her every move, making her life feel like a "spy movie".
The 43-year-old star claims she, husband Matthew Broderick and even their five-year-old son James Wilkie, are constantly chased for photo-opportunities.
Parker says, "Photographers moved into apartments next door to us and we really found ourselves kind of living like a spy movie... I feel like they think they have to be there. Like they punch in or something."